10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2018 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2018 10-K (Filed: Feb 28, 2019) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | |
| Revenues | $ 53,647 | 52,546 | 52,824 |
| Costs and expenses: | |||
| Cost of sales | 11,248 | 11,228 | 12,322 |
| Selling, informational and administrative expenses | 14,455 | 14,804 | 14,844 [1] |
| Research and development expenses | 8,006 | 7,683 | 7,892 |
| Amortization of intangible assets | 4,893 | 4,758 | 4,056 |
| Restructuring charges and certain acquisition-related costs | 1,044 | 351 | 1,565 |
| Other (income)/deductionsnet | 2,116 | 1,416 | 3,794 |
| Income from continuing operations before provision/(benefit) for taxes on income | 11,885 | 12,305 [2] | 8,351 |
| Provision/(benefit) for taxes on income | 706 | (9,049) | 1,123 |
| Income from continuing operations | 11,179 [3] | 21,353 | 7,229 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | 10 | (1) | 16 |
| Gain on disposal of discontinued operationsnet of tax | 0 | 3 | 0 |
| Discontinued operationsnet of tax | 10 | 2 | 17 |
| Net income before allocation to noncontrolling interests | 11,188 | 21,355 | 7,246 |
| Less: Net income attributable to noncontrolling interests | 36 | 47 | 31 |
| Net income attributable to Pfizer Inc. | 11,153 | 21,308 | 7,215 |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.90 | 3.57 | 1.18 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.00 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.90 | 3.57 | 1.18 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.86 | 3.52 | 1.17 |
| Discontinued operationsnet of tax (in dollars per share) | 0.00 | 0.00 | 0.00 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.87 | 3.52 | 1.17 |
| Weighted-average sharesbasic | 5,872 | 5,970 [4] | 6,089 |
| Weighted-average sharesdiluted | 5,977 | 6,058 | 6,159 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets. | |||
| [2] 2018 v. 2017The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on investments in equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from P | |||
| [3] Amounts may not add due to rounding. | |||
| [4] 2017 includes the effect of the modification for a commitment to pay 15.2 million common-share equivalents that were scheduled for near-term settlement. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2018 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |